Growth Strategy
The Chugai Group has formulated a new growth strategy, “TOP I 2030” (FY2021-FY2030) to realize our Envsioned Future, and is working on a new stage of transformation based on the strategic alliance with Roche, aiming to achieve further competitive advantage as well as sustainable profit growth and an expansion of corporate value.
Name
“TOP” expresses our aspiration to become “the world’s top innovator, not just in Japan.” The “I” has two meanings: in addition to “innovator,” it also expresses that “people” are the driving force behind value creation; each and every member of the Chugai Group plays an important role in our efforts to realize TOP I 2030.
Chugai’s Basic Policy
Companies are required to sincerely address underlying social issues and make efforts to solve them for sustainable business growth. Chugai strives to develop hand-in-hand with society by solving social issues through its business activities.
Top Innovator 2030
In collaboration with Roche, we will continue to place “innovative new drugs” at the core of our business, while aiming to become a leading innovator in the global healthcare field, where a diverse range of players, not limited to pharmaceutical companies, are taking on the challenge of innovation.
We have set our vision of “Top Innovator 2030” as shown below.
Top Innovator 2030
“Expectation from patients all over the world”
With world-class drug discovery capabilities, patients around the world expect that “Chugai will surely create new treatments.”
“Attracting talent and players from around the world”
Attract passionate talent from all over the world, and inspire players globally to think they can create something new by partnering with Chugai.
“Role model for the world”
With sustainability at the heart of its business activities, Chugai will become a global role model as a leader in resolving social issues.
Growth Strategy to become a Top Innovator 2030
While finishing mid-term business plan “IBI 21” one year earlier than scheduled, we have established a growth strategy toward 2030 – TOP I 2030 – to realize the Envisioned Future stipulated in our Mission Statement.
Growth Strategy to become a Top Innovator 2030
The two pillars of “TOP I 2030” are “Global first-class drug discovery” and a “Futuristic business model”.
Having created numerous innovative new drugs by making full use of our proprietary science and technology, we aim to significantly improve our drug discovery capabilities over the next 10 years, and to build and strengthen a system that can continuously deliver solutions that meet the world’s Unmet Medical Needs*. Specifically, we will double the current R&D output in 10 years and aim to become a company that can launch innovative in-house global products every year.
We will also work to build a futuristic business model in light of environmental changes and technological evolution. In particular, we will dramatically improve productivity across all value chains and expand value and product value for patients by dramatically restructuring processes and value creation models centered on digitization.
- * Medical need that is not adequately met due to a lack of effective treatments
5 Reforms to Realize the Top Innovator Image
In order to realize the two pillars of “TOP I 2030”, we have set forth five reforms along the value chains of “Drug Discovery,” “Development,” “Pharmaceutical Technology ,” and “Value Delivery”, as well as the “Foundation for Growth” that supports them.
5 Reforms to Realize the Top Innovator Image
1. Drug Discovery
Pursue drug discoveries based on the R&D principles*, and establish unique technologies and produce output by strengthening open innovation.
2. Development
Pursue strengthening Go/No-Go decision-making, maximizing project value and increasing of productivity by continuous transformation of operational model.
3. Pharmaceutical Technology
Pursue world-class technologies to deliver drug discovery ideas to patients as pharmaceutical products; realize highly competitive drug manufacturing technologies in terms of quality, speed, and cost.
4. Value Delivery
Pursue rapid evidence generation that contributes to optimal patient-centric treatment selection, and provide advanced value with high productivity through the establishment of a customer engagement model.
5. Foundation for Growth
New Challenges for PHC Solutions and building a foundation worthy of a Top Innovator.
Basic Principles of Increasing Corporate Value and Shareholder Returns
Chugai will target a Core EPS payout ratio of 45 percent on average while maintaining stable dividends
Chugai‘s basic strategy is to continuously generate profits and increase its corporate value by focusing on innovation and realizing advanced and sustainable patient-centric healthcare. The results will then be returned to shareholders through higher valuation in the capital markets and stable dividends.
In TOP I 2030, we will target a Core EPS payout ratio of 45 percent on average while maintaining stable dividends. We remain committed to generating steady profit growth and maintaining appropriate returns to shareholders.
